References
- Cancer incidence in Sweden 1992. The Cancer Registry, Stockholm 1993
- Dödsorsaker. ‘Causes of death’ 1992. Statistiska Centralbyrån, Stockholm 1993
- Oesterling J E. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–23
- Benson M C, Whang I S, Pantuck A, et al. Prostate-specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815–16
- Benson M C, Whang I S, Olsson C A, McMahon D J, Cooner W H. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992; 147: 817–21
- Carter H B, Pearson J D, Metter E J, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 1992; 267: 2215–20
- Oesterling J E, Chute C G, Jacobssen S J, et al. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men. J Urol 1993; 149: 412A
- Lilja H, Christensson A, Dahlén U, et al. Prostate specific antigen in human serum occurs predominantly in complex with alpha-1-anti-chymotrypsin. Clin Chem 1991; 37: 1618–25
- Stenman U H, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1-antichymo-trypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. Cancer Res 1991; 51: 222–6
- Oesterling J E, Jacobsen S J, Chute C G, et al. Serum prostate-specific antigen in a community-based population of healthy men. J Am Med Assoc 1993; 270: 860–4
- Collins G N, Lee R J, McKelvie G B, Rogers A CN, Hehir M. Relation between prostate-specific antigen prostate volume and age in the benign prostate. Br J Urol 1993; 71: 445–50
- Oesterling J E, Kumamoto Y, Tsukamoto T, et al. Serum prostate-specific antigen in community-based population of healthy Japanese men: lower values than for similarly aged Caucasians. Br J Urol 1995; 75: 347–53
- Dixon W J. Processing data for outliers. Biometrics 1983; 9: 74–89
- Solberg H E. Statistical treatment of collected reference values. Determination of reference limits. Approved recommendation (1987) on the theory of reference values. Part 5. (Int. Federation of Clinical Chemistry). Clin Chim Acta 1987; 170: S13–S32
- Henry R J, Reed A H. Normal values and the use of laboratory results for the detection of disease. Clinical Chemistry. Principles and techniques2nd ed., R J Henry, D C Cannon, J W Winkelman, Magerstown 1974; 343–71
- Babaian R J, Miyashita H, Evans R B, Ramirez E I. The distribution of prostate-specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland volume and age. J Urol 1992; 147: 837–40
- Dalkin B L, Ahmann F R, Kopp J B. Prostate-specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993; 150: 1837–9
- Bosch J LHR, Hop W CJ, Bangma C H, Kirkels W J, Schröder F H. Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of pros-tatism. The Prostate 1995; 27: 241–9
- Catalona W J, Hudson M A, Scardino P T, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1997; 152: 2037